The U.S. Meals and Drug Administration (FDA) just lately introduced that it had granted a nationwide precedence overview voucher to Tecvayli (teclistamab) together with Darzalex (daratumumab) for sufferers with relapsed/refractory a number of myeloma, within the wake of findings from the MajesTEC-3 medical trial being printed in The New England Journal of Medication and shared at
CURE sat down for an interview with Dr. Surbhi Sidana, chair of the American Society of Hematology’s Committee on Communications and affiliate professor of drugs at Stanford College, to debate this therapy mixture and what its approval by the FDA would imply for sufferers with a number of myeloma.
CURE: For sufferers with a number of myeloma, what’s the significance of the MajesTEC-3 findings that have been offered at ASH in 2025 ?
Sidana: For many who usually are not accustomed to MajesTEC-3, it is a randomized part 3 trial of [Darzalex] and [Tecvayli] versus normal of care, which is [Darzalex]-based remedy, [Darxalex and Pomalyst (pomalidomide), DPd, or Velcade (bortezomib), DVd].
The [profession-free survival (PFS)] profit that we noticed was like unprecedented, with important enchancment in comparison with normal of care, which did simply as nicely, if not barely higher, than anticipated. And we’ve got not seen this exceptional PFS, a three-year estimate, with anything. So, for the primary time with this mixture — that’s, aside from infections, pretty nicely tolerated — we’re seeing very extended remissions in sufferers. So, I feel that is really transformative.
How would this transformation the therapy panorama for sufferers, if this therapy mixture is authorized by the FDA?
Presently, bispecific antibodies, whether or not it is [Tecvayli] or different BCMA bispecifics or GPRC5D bispecifics, all of them are authorized for late relapse as four-plus traces of remedy. This may be the primary bispecific antibody, given it is a mixture, to be authorized for early relapse. So proper now, this will increase choices for early relapse tremendously.
Proper now, we’ve got chemotherapy-based choices. We now have CAR-T cell remedy, and now it will permit us to make use of bispecific antibodies. I’ll say that not everyone is ready to entry CAR-T cell remedy as a result of they could not stay nearer to a middle, they could not wish to journey, although there’s exceptional success when it comes to effectiveness and treatment-free interval. However for these sufferers, this offers an immunotherapy choice to them, maybe nearer to dwelling, than CAR-T cell remedy if they do not stay near a middle.
In patient-friendly phrases, how does this therapy mixture work to deal with a number of myeloma?
It is a mixture of an immunotherapy, a bispecific antibody, [Tecvayli], which binds to myeloma cells and brings a affected person’s personal immune killing cells, lymphocytes, near the myeloma cells in order that the lymphocytes can do the killing. It has two arms, one facet that binds to the immune cells and the opposite facet that binds to the myeloma cells. [Darzalex] is a monoclonal antibody that identifies a marker on the myeloma cells that is completely different than [Tecvayli], CD38 and permits, once more, direct killing and in addition immune-mediated killing of the myeloma cell.
So, none of them are chemotherapy. One is a monoclonal antibody, and the opposite is a bispecific antibody, after which collectively, they seem like synergistic, not simply additive. And the best way we predict the synergy works is that [Darzalex] additionally depletes the physique of some immune cells that aren’t useful, that is likely to be really defending the most cancers or stopping the motion of those medicine. So I feel that is essential, and it is essential as a result of when this trial was executed, not many sufferers have been uncovered to [Darzalex] as frontline remedy. 5 % of sufferers had prior publicity to [Darzalex] on this trial. Effectively, now everyone will get [Darzalex] in frontline remedy, and lots of sufferers would even be refractory to [Darzalex]. Which means their most cancers has develop into immune to [Darzalex].
That is a giant query within the subject. Ought to we be utilizing [Darzalex] together with [Tecvayli] for sufferers who’re immune to [Darzalex]? Will it do one thing there? And I feel the jury is out, however one potential manner could be it’s going to nonetheless assistance is to stop these dangerous immune cells from interfering with the response. In order that’s one risk. So, I feel if somebody’s uncovered to [Darzalex], I undoubtedly wouldn’t have any hesitation in utilizing [Darzalex] once more, however say they have been simply on [Darzalex] a month or two in the past, I feel that is the place we really do not know if that will work or not.
References
- “FDA Proactively Awards Nationwide Precedence Voucher Based mostly on Sturdy Part 3 Research Outcomes,” FDA; https://www.fda.gov/news-events/press-announcements/fda-proactively-awards-national-priority-voucher-based-strong-phase-3-study-results
- “Tecvayli Remedy Combo Improves Outcomes in Relapsed/Refractory Myeloma,” CURE; https://www.curetoday.com/view/tecvayli-treatment-combo-improves-outcomes-in-relapsed-refractory-myeloma
Transcript has been edited for readability and conciseness.
For extra information on most cancers updates, analysis and schooling, don’t overlook to
